CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CardioGenesis Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CardioGenesis Corporation
11 Musick
Phone: (949) 420-1800p:949 420-1800 Irvine, CA  92618  United States Ticker: CGCPCGCP

This company was Merged or Acquired on 5/17/2011.
This company ceased filing statements with the SEC on 5/17/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
CardioGenesis Corporation develops and markets surgical products for the treatment of refractory angina in patients with chronic cardiac ischemia caused by coronary artery disease (CAD), which remains a cause of death for persons over the age of 65. the Company’s products are used to create transmural laser channels into the myocardium, commonly referred to as transmyocardial revascularization (TMR), which has proven effective in reducing symptoms in patients with refractory angina compared to optimal medical management. Its PHOENIX Combination Delivery System is a device developed for this purpose. In December 2009, the Company filed an investigational device exemption (IDE) to obtain United States Food and Drug Administration (FDA) approval to begin a clinical trial for its PHOENIX Combination Delivery System. In May 2011, CryoLife, Inc. acquired the Company.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201112/31/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Principal Executive Officer Paul J.McCormick 58 7/1/2009 4/19/2007
Chief Financial Officer, Senior Vice President, Treasurer, Secretary William R.Abbott 53 5/22/2006 5/22/2006
Executive Vice President - Marketing Richard P.Lanigan 50 7/1/2009 3/1/2000
4 additional Officers and Directors records available in full report.

Business Names
Business Name
CGCP
CGCP Corp.
Compleat, Inc.
Eclipse Surgical Technologies B.V.

General Information
Number of Employees: 32 (As of 12/31/2010)
Outstanding Shares: 46,535,403 (As of 5/2/2011)
Shareholders: 226
Stock Exchange: OTC
Federal Tax Id: 770223740


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023